Survey indicates most Nationwide members believed false alarms from patient motion were a significant distraction to care, emphasizing the need for
more advanced pulse oximetry technology
IRVINE, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Nationwide Respiratory and Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, announced that they have entered into a preferred provider agreement making Masimo SET pulse oximetry technology available to Nationwide's network of over 150 independent respiratory homecare providers. Masimo SET is the most accurate and reliable pulse oximetry technology, clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion.
Nationwide Respiratory, part of the VGM Group -- the nation's largest member service organization for Home Medical Equipment (HME) -- is a national network of over 150 independent respiratory homecare providers in the U.S. with more than 400 locations. These homecare providers use the pulse oximeter to assess the oxygen saturation of a patient during overnight sleep tests in order to determine whether or not the patient meets established Medicare or private insurance guidelines for home oxygen therapy.
Tom Pontzius, President, Nationwide Respiratory, stated "The ability to detect and capture true hypoxic events, in real-time, are essential in the administration of overnight oxygen saturation sleep tests; however, inaccurate readings and false data due to motion have hindered the effectiveness of these tests for our members. The accuracy and reliability of the pulse oximeter, even through patient motion, is crucial to effectively qualifying a patient for home oxygen therapy. Medicare guidelines cover home oxygen therapy if a patient's SpO2 drops below 89% for at least 5 minutes with a mean of 85% or less in an overnight sleep test. Getting this data correct is absolutely vital to ensuring a patient receives adequate respiratory homecare. Based on third party clinical literature and our surveys, we concluded that Masimo is by far the best choice for detecting hypoxemias and hypopneas and reducing false alarms."
Joe E. Kiani, Chairman and CEO of Masimo, said, "Nationwide Respiratory is one of the nation's leading independent home respiratory provider networks. Dedicated to providing selection, service and support during the entire sleep apnea diagnosis and treatment process, Nationwide Respiratory has taken the proactive steps necessary to help its members advance the level of care they deliver. They recognized that their members have significant challenges with their current pulse oximetry solutions and were willing to invest in advanced technology, like Masimo SET, to resolve them. We are excited to partner with Nationwide Respiratory and look forward to meeting the pulse oximetry needs of their members."
As part of the contracting process, Nationwide Respiratory surveyed all its members to better understand their needs in the care of their patients with pulse oximetry. The results revealed the need for more advanced pulse oximetry technology as members overwhelmingly cited reduction in false alarms and more accurate/reliable data as reasons for their need to switch to a better pulse oximetry technology.
Reduction in False Alarms
The majority of members surveyed said that SpO2 false alarms due to patient motion are the most common type of alarms, generating the greatest number of phone calls from patients in the home. As a result, most Nationwide members surveyed said they would invest in technology if it could reduce false alarms due to motion.
Masimo SET is a breakthrough Read-Through Motion and Low Perfusion pulse oximetry technology that uses advanced breakthrough signal processing algorithms to deliver accurate and reliable SpO2 and pulse rate measurements. By delivering meaningful alarms and alerts that can be trusted to reflect a patient's true oxygenation status, clinicians can maximize their efficiency by concentrating on caring for their patients, rather than chasing false alarms.
More Accurate and Reliable Oxygen Saturation Data
Nationwide Respiratory members also confirmed that as many as 40% of overnight oximetry tests do not capture enough "real" hypoxic events and most survey respondents said they would invest in a more powerful oximetry technology if it was proven to capture more 'real' hypoxic events and improve the effectiveness of their overnight oximetry program.
Unlike conventional pulse oximeters, Masimo SET provides the greatest sensitivity (ability to detect true positives), at 98%, with the greatest specificity (the ability to reject false positives), at 97%, based on independent and objective evaluations and studies that have examined oximeter performance in real clinical environments. In fact, in a pediatric sleep laboratory setting, Masimo SET technology was found to accurately detect hypopneas 98.6% of the time, while Nellcor detected only 45.3% -- missing greater than 50% of pediatric hypopneas.(1)
"As a result of this survey, we heard our members loud and clear and have chosen to partner with Masimo because they are the leader in oximetry technology," said Tom Pontzius, President Nationwide Respiratory.
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Read-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET, and with it virtually eliminated false
alarms and increased pulse oximetry's ability to detect life-threatening
events. Masimo SET is the most accurate and reliable pulse oximetry
technology, clinically proven in more than 100 independent and objective
studies to provide the most trustworthy SpO2 and pulse rate measurements
even under the most difficult clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow
SET, a breakthrough noninvasive blood constituent monitoring platform that
can measure many blood constituents that previously required invasive
procedures. Rainbow SET continuously and noninvasively measures
carboxyhemoglobin (SpCO) and methemoglobin (SpMet), pleth variability index
(PVI), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse
rate, allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about
Masimo and its products may be found at http://www.masimo.com.
(1) Differences in Pulse Oximetry Technology can Affect Detection of
Sleep-Disordered Breathing in Children. Robert Brouillette, Jacinthe
Lavergne, Andra Leimanis, Gillian Nixon, Sylvia Ladan, Christine
McGregor. Department of Pediatrics, Montreal Children's Hospital,
McGill University, Montreal, Quebec, Canada.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpCO, SpMet, PVI and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Contact: Tom McCall
|SOURCE Masimo Corporation|
Copyright©2007 PR Newswire.
All rights reserved